Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05875285
Other study ID # Nayera_Radwan_2023
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 1, 2023
Est. completion date October 1, 2023

Study information

Verified date May 2023
Source Cairo University
Contact Nayera Radwan
Phone +201000206016
Email nayera.radwa55@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to compare the therapeutic effect of methotrexate iontophoresis versus coal tar ointment on the the treatment of primary palmer hyperhidrosis?


Description:

Some researchers stated that hyperhidrosis can render the skin susceptible to infection because of the continuous dampness of the skin. The condition may become socially, psychologically and professionally debilitating. There are a lot of literatures concerned with studying the modalities used in the treatment of primary palmar hyperhidrosis, so this study will be conducted to compare between two of them and to show the best one for treating primary palmar hyperhidrosis.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date October 1, 2023
Est. primary completion date August 20, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 15 Years to 35 Years
Eligibility Inclusion Criteria: - Patient with primary palmar hyperhidrosis to extend that their palms are wet during most of the day (score 3 and 4 in the Hyperhidrosis Disease Severity Scale) was included in this study. - The palmer hyperhidrosis patient's age ranged from 15 to 35 years. - All patients will be examined by dermatologist before starting the study. Exclusion Criteria: The study excluded the following patients: - Patients with medical conditions that associated with hyperhidrosis are excluded, these conditions include:- hyperthyroidism, diabetes mellitus, parkinsonism, spinal cord injury, brain damage, congestive heart failure, anxiety, alcoholism and menopause. - Patients who received any treatment with a drug that was affecting sweating e.g. (thyroxin, anxiolytics…..) that is not stopped at least 4 weeks preceding the study. - Patients with cardiac conditions such as arrhythmia, ischemic heart disease, low exercise tolerance, low respiratory reserve were excluded. - Patients, who have a local wound, sever eczema and severe fungal infection of the palms to minimize risk of local burn. - Patients who have sensory disorders. - Female patients who are pregnant and lactating.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Iontophoresis with methotrexate
The methotrexate iontophoresis group the patient's hands are placed in direct contact with the conductive electrodes. The patient will receive full explanation to the purpose of the treatment, the therapeutic and physiological benefits of this method of treatment. Before starting the treatment, all the previous measurements of each patient in this group is taken for a comparison. Every patient will receive 12 sessions 3times/week every session consist of 30 minutes application of methotrexate iontophoresis using continuous direct current, the patient should feel mild tingling sensation (not painful), the polarity should be reversed halftime of treatment session, as the anodal current is more effective.
Iontophoresis with coal tar ointement
For coal tar ointement group the ointement is putted direct on the skin after describing the instruction and method of application and time of application and do alarm instead not to forget.

Locations

Country Name City State
Egypt Outpatient clinic faculty of physical therapy cairo university Cairo

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessing the change in Sweat output Sweat output was objectively measured by recording mass gained by a standard diaper of approximately 30gm that was placed in contact with palms for 10 minutes and then was weighted using laboratory mass scale at baseline and after 4 weeks of intervention
Primary Assessing the change in degree of severity of hyperhidrosis By using Hyperhidrosis disease severity scale. It is a (4) points scale that is used to determine the degree of severity of hyperhidrosis at baseline and after 4 weeks of intervention
See also
  Status Clinical Trial Phase
Completed NCT04924036 - Qbrexza Cloths for Hyperhidrosis of Amputation Sites Phase 2
Recruiting NCT05102396 - Topical Oxybutynin for Treatment of Hyperidrosis: Local or Systemic Effect? Phase 2
Recruiting NCT04178161 - Image Guided Targeted Photoablation for the Treatment of Localized Hyperhidrosis N/A
Completed NCT02565732 - Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis Phase 2
Completed NCT02552199 - A Non-Interventional Study To Assess Sweating
Recruiting NCT01930604 - Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis Phase 2
Completed NCT01811004 - Evaluation of 1440nm Laser vs. Botulinum Toxin or miraDry® Microwave For Treatment of Axillary Hyperhidrosis N/A
Completed NCT01671800 - Study to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis-associated Sweating Phase 1
Completed NCT01956591 - Long Term Results of the Use of Oxybutynin for the Treatment of Hyperhidrosis N/A
Completed NCT01934153 - Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects Phase 1
Completed NCT06113978 - Thoracoscopic Sympathetic Chain Interruption for Palmar Hyperhidrosis in Patients Below 18 N/A
Completed NCT04906655 - An Open Label Study for Palmar Hyperhydrosis Phase 2
Completed NCT05247333 - Implementation of a Minor Ailment Service in Community Pharmacy Practice N/A
Completed NCT02563899 - Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis Phase 2
Withdrawn NCT05546710 - miraDry Post Market Tumescent Anesthesia Study N/A
Completed NCT02016885 - A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis Phase 2
Completed NCT00168480 - A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis Phase 4
Completed NCT03416348 - Hyperhidrosis, Developing a Treatment Approach Aims 1 & 2 Phase 1
Completed NCT02973659 - The Use of Topical Oxybutynin 10% for Treating Primary Focal Hyperhidrosis-axillary, Palmar and Plantar. N/A
Recruiting NCT05805696 - Treatment and Mapping of Impostor Phenomenon N/A